Skip to content

SUCCESS PTA Study: SELUTION SLR* safety, efficacy, health economics and proms.

SUCCESS PTA Study: SELUTION SLR* safety, efficacy, health economics and proms. - SUCCESS PTA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50785
Enrollment
30
Registered
2021-04-21
Start date
2022-07-04
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Artery Disease

Interventions

None listed

Sponsors

M.A. Med Alliance SA
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Subject age is >= 18 years 2. Subject is able and willing to provide informed consent 3. Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the current Instruction for use

Exclusion criteria

Exclusion criteria: Subjects who meet one or more of the following criteria will be excluded from the study: 1. In the opinion of the treating investigator the subject has a life expectancy of less than 12 months 2. In the opinion of the treating investigator the subject is unlikely to comply with the study follow-up regime

Design outcomes

Primary

MeasureTime frame
The primary endpoint will be freedom from Clinically Driven Target Lesion Revascularisation (CD-TLR) at 1-year post-intervention.

Secondary

MeasureTime frame
- Device success: Successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure. [at end of procedure] - Procedure success: Device success and residual stenosis

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)